呼吸器合胞体ウイルス(RSV)ワクチン:世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: Respiratory Syncytial Virus (RSV) vaccines - Global vaccine commercial opportunity assessment [52 countries]
◆商品コード:VAZ2006014
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2019年3月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (~220 slides.pdf) + 2 x MS-Excel forecast model(s) (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD11,995 ⇒換算¥1,247,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Human respiratory syncytial virus (RSV) is one of the most common viruses to infect children worldwide and now increasingly is recognized as an important pathogen in adults, especially the elderly. Globally each year, there are over 33m episodes of RSV-associated acute lower respiratory infection in children younger than 5 yrs of age resulting at least 3.2m hospital admissions and 59,600 in hospital deaths (2015 estimation, Shi T et al., 2017). In children below 5 yrs, the burden of RSV exceeds that of influenza and other respiratory viral pathogens. There is no specific treatment for RSV infection and for those children who require hospitalization (~1-2% of healthy), supportive therapy is still the mainstay of care. Palivizumab (anti-RSV monoclonal, Synagis®) has been FDA approved since 1998 for the prophylaxis of specific subsets of premature infants.
Despite serious setbacks in the late 1960s with a formalin-inactivated RSV vaccine, the RSV vaccine development field is now one of the most active in the industry. Major companies such as Pfizer, GSK Biologicals, Janssen NV and smaller biotech’s e.g. Novavax have a range of vaccine approaches in active clinical development targeting all the recognized target populations. Newer long-acting monoclonal antibodies such as MEDI8897 (MedImmune) are also being pursued.

This MarketVIEW product is a comprehensive Executive Presentation (~225 slides, .pdf) and 2 MS-Excel forecast models which investigate the scenario-based interplay and commercial potential of four RSV vaccine profiles in all relevant target groups (e.g. maternal, infant, adult “at risk” and elderly) to 2035. 52 countries and sub-regions are included in the model with expected public and private sector vaccination being indicated. A methodology has been created whereby country specific roll-out is forecasted according to specific local factors and RSV transmission patterns which may in turn influence RSV program adoption. The report contains a thorough review of current disease background/epidemiology/CE and vaccinology with an emphasis on structural-based antigen engineering. An analysis of the R&D competitive environment (including long acting mAbs) is also provided with an in-depth discussion of the latest ResVax (Novavax) PREPARE Phase III data. This product is ideally suited to organisations wishing to access an up-to-date advanced global quantification of the RSV vaccine opportunity.

THIS PRODUCT IS A SUMMARY PRESENTATION (~225 slides, .pdf) + 2 scenario-based MS Excel Workbook(s)
Photo credit: Picsea @picsea

To order please contact your region account manager, buy “on-line” or order direct at: orders@vaczine-analytics.com

【レポートの目次】

PRODUCT CONTENTS:
Published March 2019 (CAT No: VAMV023)
****This product is a summary presentation (.pdf), a forecast model (.xls)
Contents – Summary presentation (.pdf)2
Contents
Author’s notes
Executive summary
[SECTION 1] RSV vaccines: key commercial model outputs
[SECTION 2] RSV: introduction to the virus and disease background
[SECTION 3] RSV: disease epidemiology (infants & children)
[SECTION 4] RSV: disease epidemiology (adults and elderly)
[SECTION 5] RSV: vaccinology
[SECTION 6] RSV: vaccine research and development (R&D) pipeline
[SECTION 7] RSV: vaccines: modelling commercial potential
Bibliography
About VacZine Analytics
Disclaimer
PAGES: ~220 slides fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand models x 2 (MS Excel-based)
Worksheets = >90 interconnected



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[呼吸器合胞体ウイルス(RSV)ワクチン:世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆